Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income: 2016-2024

Historic Net Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $275.2 million.

  • Protagonist Therapeutics' Net Income fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.15%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • As of FY2024, Protagonist Therapeutics' Net Income stood at $275.2 million, which was up 448.54% from -$79.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Net Income registered a high of $275.2 million during FY2024, and its lowest value of -$127.4 million during FY2022.
  • Its 3-year average for Net Income is $22.9 million, with a median of -$79.0 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 73.81% in 2021, then surged by 448.54% in 2024.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Net Income stood at -$72.4 million in 2020, then slumped by 73.81% to -$125.8 million in 2021, then dropped by 1.27% to -$127.4 million in 2022, then soared by 38.02% to -$79.0 million in 2023, then soared by 448.54% to $275.2 million in 2024.